Bilous I. Clinico-pathogenetic substrantiation of using mildronat and tiotriazolin in multimodality treatment of patients with diabetic polyneuropathy

The research has analyzed the specific characteristics of the course of diabetic polyneuropathy and investigated the content of the products of lipid peroxidation, oxidative modification of proteins, the state of the blood antioxidant system, the function of the peripheral nerves by means of stimulation electroneuromyography in 126 patients suffering from dibetes mellitus with diabetic polyneuropathy. It has been ascertained that an activation of the processes of lipid peroxidation, a suppression of the activity of the protective antioxidant systems and enhancement of the blood oxidative modification of proteins, a decrease of the amplitude of m-response and the velocity of carrying out the stimulation by the motor fibers of the peripheral nerves are already observed during the first year of diabetes mellitus disease and a further reduction of these parameters as the duration of the disease increased. It has been proved that the application of mildronats and tiotriazolin in the multimodality therapy ofpatients with diabetic polyneuropathy in contrast to ordinary basic therapy has detected a suppression of lipid peroxidation processes, an angmentation of the activity of the protective antioxidant system, a decrease of the blood oxidative modification of proteins. The best effect was observed in case of a simultaneous administration of mildronat and tiotriazolin in all three groups. The clinical efficacy of multimodality therapy with the use of mildronat and tiotriazolin exceeds that which is achieved with basic therapy, the latter being demonstrated by a significant regression of complaints and neurologic symptomatology. Improved nerve conduction under the influence of triazolin and mildronat has been noted in patients with the duration of dibetes mellitus up to 10 years. It is evidenced by a reliable increase of the speed of performing stimulation and the amplitude of m-response. The best result is observed with a simultanevus administration of mildronat and tiotriazolin. The dosage schedule of these medications in multimodality treatment of patients with diabetic pylyneuropathy has been developed and introduced into clinical practice.